MHM Magazine

prolonged release suspension for injection paliperidone palmitate TREVICTA ® THE TREVICTA ® PLAN * Help your patients to take ownership of their schizophrenia with the enduring efficacy and convenience of the unique four-per-year (4PY) TREVICTA ® . 1,2,3,4,5,6 What’s your plan for your patients living with schizophrenia? DAILY ORALS Risperidone/ Paliperidone. 8,9 MONTHLY XEPLION ® Paliperidone Palmitate. 8 4 PER YEAR TREVICTA ® Paliperidone Palmitate. 7 References: 1. Schreiner A, Bergmans P, Cherubin P, et al. A Prospective Flexible-Dose Study of Paliperidone Palmitate In Nonacute But Symptomatic Patients With Schizophrenia Previously Unsuccessfully Treated With Oral AntipsychoticAgents. ClinicalTherapeutics 2014;36(10):1372-1388e1.2.Berwaerts J,LiuY,Gopal S,et al.Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia. A Randomized Clinical Trial. JAMA Psychiatry 2015;72(8):830-839. 3. Savitz A, Xu H, Gopal S, et al. Efficacy and Safety of Paliperidone Palmitate 3-Monthly Formulation for Patients with Schizophrenia:A Randomized, Multicenter, Double-Blind, Noninferiority Study. International Journal of Neuropharmacology 2016;19(7):1-14. 4. Hargarter L, Bergmans P, Cherubin P, et al. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. Expert Opinion on Pharmacology 2016;17(8):1043-1053. 5. Caroli F, Raymondet P, Izard I, et al. Opinions of French patients with schizophrenia regarding injectable medication. Patient Preference and Adherence 2011;5:165-171. 6. Gopal S,Vermeulen A, Nandy P, et al. Practical Guidance for Dosing and Switching from Paliperidone Palmitate 1-Monthly to 3-Monthly Formulation in Schizophrenia. Current Medical Research and Opinion 2015;31(1):2043-2054. 7.TREVICTA® Professional Information Leaflet. December 2020. 8. Xeplion Professional Information Leaflet. May 2019. 9. INVEGA ® Professional Information Leaflet. January 2010. * The TREVICTA ® Plan is the initiation of XEPLION ® then moving to TREVICTA ® when stabilised - in line with the approved indications for both treatments. 7 XEPLION ® is indicated for maintenance treatment of schizophrenia and for the prevention of recurrence of symptoms of schizophrenia. 8 TREVICTA ® , a 3-monthly injection is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1-monthly paliperidone palmitate injectable product. 7 S5 TREVICTA ® 175 mg,263 mg,350 mg,525 mg prolonged release suspension for injection.175 mg prolonged release suspension for injection:Each pre-filled syringe contains 273 mg paliperidone palmitate equivalent to 175 mg paliperidone.263 mg prolonged suspension for injection:Each pre-filled syringe contains 410 mg paliperidone palmitate equivalent to 263 mg paliperidone.350 mg prolonged release suspension for injection:Each pre-filled syringe contains 546 mg paliperidone palmitate equivalent to 350 mg paliperidone. 525 mg prolonged release suspension for injection: Each pre-filled syringe contains 819 mg paliperidone palmitate equivalent to 525 mg paliperidone. MarketingAuthorisation Number/s: EU/1/14/971/007; EU/1/14/971/008; EU/1/14/971/009; EU/1/14/971/010. For full prescribing information, refer to the latest professional information leaflet. December 2020. S5 XEPLION ® 50, 75, 100 or 150mg Prolonged release suspension for intramuscular injection. Each pre-filled syringe contains sterile paliperidone palmitate equivalent to 50, 75, 100 or 150mg of paliperidone respectively. Reg. Nos.:44/2.6.5/0866; 44/2.6.5/0867; 44/2.6.5/0868;44/2.6.5/0870. For full prescribing information, refer to the latest professional information insert. May 2019. JANSSEN PHARMACEUTICA (PTY) LTD, (Reg. No. 1980/011122/07), No 2, Medical Street, Halfway House, Midrand, 1685. www.janssen.com . Medical Info Line: 0860 11 11 17. CP-243117